Navigation Links
Switching an antibiotic on and off with light
Date:3/21/2014

This news release is available in German.

Scientists of the KIT and the University of Kiev have produced an antibiotic, whose biological activity can be controlled with light. Thanks to the robust diarylethene photoswitch, the antimicrobial effect of the peptide mimetic can be applied in a spatially and temporally specific manner. This might open up new options for the treatment of local infections, as side effects are reduced. The researchers present their photoactivable antibiotic with the new photomodule in a "Very Important Paper" of the journal "Angewandte Chemie".

Photoswitchable molecules modify their structure and properties when exposed to light of an adequate wavelength. Among the photoswitches known are diarylethenes. By reversible photoisomerization, i.e. a reversible light-induced internal relocation of the molecule, the open form is turned into a closed form. Such photoswitch-able molecules are applied in molecular electronics and many other areas. Particularly interesting opportunities result from the insertion of photoswitches into biomolecules to control their activity by light. Interest focuses on so-called peptide mimetics, compounds whose major structural elements emulate a peptide, i.e. a small protein.

For the first time now, a group of researchers headed by Professor Anne S. Ulrich, Director of the Institute for Biological Interfaces 2 (IBG2) and holder of the Chair for Biochemistry at the Institute of Organic Chemistry (IOC) of KIT, has produced a photoswitchable peptide mimetic based on a diarylethene scaffold that can be photoisomerized reversibly. The scientists modified this building block into an amino acid analog and incorporated it directly into the backbone of the annular peptide antibiotic Gramicidin S. Biological activity of the resulting peptide mimetic can be controlled spatially and temporally with the help of UV and visible light. To demonstrate this, the scientists treated a bacterial film with the inactivated antibiotic and exposed it to light via a mask. As a result, the photoswitchable diarylethene was converted from a closed into an open form. Due to the structural modification induced, the entire substance molecule had a much higher antimicrobial effect. "In the future, such photoactivable antibiotics might be used as smart therapeutic agents against local bacterial infections," Professor Anne S. Ulrich explains. "Usual side effects can also be minimized by switching." Based on this strategy, new peptide-based agents against cancer might be feasible, as the newly developed photoactivable building block can also be applied in other peptide sequences.

The editors of the journal "Angewandte Chemie", in which the researchers of KIT and the University of Kiev present their photo-activable antibiotic and their photoswitch, have rated this publication a "VIP Very Important Paper".


'/>"/>

Contact: Monika Landgraf
presse@kit.edu
49-721-608-47414
Karlsruher Institut fr Technologie (KIT)
Source:Eurekalert  

Related biology news :

1. How phenotype switching can make melanoma become metastatic and resistant to drugs
2. Comeback of an abandoned antibiotic
3. Fighting antibiotic resistance with molecular drill bits
4. A tricky balancing act: Antibiotics versus the gut microbiota
5. Spread of antibiotic resistance understood by unravelling bacterial secretion system
6. UT Arlington undergrad honored for research on antibiotic resistant infection
7. Notre Dame chemists discover new class of antibiotics
8. Fossilized human feces from 14th century contain antibiotic resistance genes
9. €85 million for new way to carry out antibiotic drug discovery
10. Promising class of antibiotics discovered for treatment of drug-resistant tuberculosis
11. Drug alternatives to antibiotics may not be perfect, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Switching an antibiotic on and off with light
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology: